Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95455
UPID:
TGDS_HUMAN
Alternative names:
-
Alternative UPACC:
O95455; Q05DQ3; Q2TU31; Q5T3Z2; Q9H1T9
Background:
The protein dTDP-D-glucose 4,6-dehydratase, encoded by the gene with accession number O95455, plays a crucial role in the biosynthesis of dTDP-L-rhamnose, a sugar essential for the cell wall integrity in bacteria and plant cells. Its enzymatic activity is pivotal in converting dTDP-D-glucose into dTDP-4-keto-6-deoxy-D-glucose, a precursor in the synthesis of dTDP-L-rhamnose.
Therapeutic significance:
Understanding the role of dTDP-D-glucose 4,6-dehydratase could open doors to potential therapeutic strategies. Specifically, its involvement in Catel-Manzke syndrome, a genetic disorder characterized by unique skeletal abnormalities and cleft palate, highlights its potential as a target for therapeutic intervention. Developing inhibitors for this enzyme could offer a novel approach to treat this syndrome.